Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells
AssigneeHelmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
InventorsDolores Schendel, Rudolf Wank
Life of this patent
Estimating the term…
Abstract
The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.
Claims4
A method for the generation of HLA-haploidentical antigen-presenting cells for the treatment of tumor diseases in a patient comprising the following steps:
- providing a patient to be treated;
- providing antigen-presenting cells from a semi-allogeneic donor which are HLA-haploidentical with respect to those of the patient, wherein HLA-haploidentical antigen-presenting cells have class I and class II molecules in common with the patient;
- and
- introducing proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides into the HLA-haploidentical antigen-presenting cells, wherein said proteins and/or peptides are tumor-defined antigens or wherein said RNA or DNA or cDNA encodes tumor-defined antigens, wherein the tumor-defined antigens are antigens overexpressed in the tumor cells, wherein the tumor-defined antigens are selected from the group consisting of oncogenes, proteins providing a growth advantage to the tumor and/or ensuring its survival, cell cycle regulatory proteins, transcription factors, mucins, and proteins involved in the regulation of cell division.
A method for the generation of HLA-haploidentical antigen presenting cells for the treatment of tumor diseases in a patient comprising the following steps:
- providing a patient to be treated;
- providing antigen-presenting cells from a semi-allogeneic donor which are HLA-haploidentical with respect to those of the patient, wherein HLA-haploidentical antigen-presenting cells have class I and class II molecules in common with the patient, wherein antigen-presenting cells of two different HLA-haploidentical individuals are used;
- and
- introducing proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides into the HLA-haploidentical antigen-presenting cells, wherein said proteins and/or peptides are tumor-defined antigens or wherein said RNA or DNA or cDNA encodes tumor-defined antigens, wherein the tumor-defined antigens are antigens overexpressed in the tumor cells, wherein the tumor-defined antigens are selected from the group consisting of oncogenes, proteins providing a growth advantage to the tumor and/or ensuring its survival, cell cycle regulatory proteins, transcription factors, mucins, and proteins involved in the regulation of cell division.
A method of treatment of tumor diseases in a patient comprising administering to said patient a therapeutically effective amount of semi-allogeneic HLA-haploidentical antigen presenting cells into which proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides have been introduced, wherein HLA-haploidentical antigen-presenting cells have class I and class II molecules in common with the patient, and wherein said proteins and/or peptides are overexpressed in tumor cells or derived from autologous tumor cells, and wherein said HLA-haploidentical antigen-presenting cells are administered by the intravenous, subcutaneous or intramuscular route.
A method of treatment of tumor diseases in a patient comprising administering to said patient a therapeutically effective amount of semi-allogeneic HLA-haploidentical antigen presenting cells into which proteins and/or peptides or RNA or DNA or cDNA encoding said proteins and/or peptides have been introduced, wherein HLA-haploidentical antigen-presenting cells have class I and class II molecules in common with the patient, wherein HLA-haploidentical antigen-presenting cells of two different HLA-haploidentical individuals are used;
- and wherein said proteins and/or peptides are overexpressed in tumor cells or derived from autologous tumor cells, and wherein said HLA-haploidentical antigen-presenting cells are administered by the intravenous, subcutaneous or intramuscular route.
Dependencies are inferred from the claim text.